These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38381052)

  • 1. Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED.
    Bu G; Danelius E; Wieske LHE; Gonen T
    Adv Biol (Weinh); 2024 May; 8(5):e2300570. PubMed ID: 38381052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED.
    Bu G; Danelius E; Wieske LH; Gonen T
    bioRxiv; 2023 Sep; ():. PubMed ID: 37781611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy.
    Miao M; Jing X; De Clercq E; Li G
    Drug Des Devel Ther; 2020; 14():2759-2774. PubMed ID: 32764876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
    Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
    J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir.
    Timm J; Kosovrasti K; Henes M; Leidner F; Hou S; Ali A; Kurt Yilmaz N; Schiffer CA
    ACS Chem Biol; 2020 Feb; 15(2):342-352. PubMed ID: 31868341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).
    Ezat AA; El-Bialy NS; Mostafa HI; Ibrahim MA
    Protein J; 2014 Feb; 33(1):32-47. PubMed ID: 24374429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T; Namasivayam V; Manickam M
    Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi
    Taylor JG; Zipfel S; Ramey K; Vivian R; Schrier A; Karki KK; Katana A; Kato D; Kobayashi T; Martinez R; Sangi M; Siegel D; Tran CV; Yang ZY; Zablocki J; Yang CY; Wang Y; Wang K; Chan K; Barauskas O; Cheng G; Jin D; Schultz BE; Appleby T; Villaseñor AG; Link JO
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2428-2436. PubMed ID: 31133531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance.
    Zephyr J; Nageswara Rao D; Vo SV; Henes M; Kosovrasti K; Matthew AN; Hedger AK; Timm J; Chan ET; Ali A; Kurt Yilmaz N; Schiffer CA
    J Mol Biol; 2022 May; 434(9):167503. PubMed ID: 35183560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective.
    Boonma T; Nutho B; Rungrotmongkol T; Nunthaboot N
    Comput Biol Chem; 2019 Dec; 83():107154. PubMed ID: 31751885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.
    Bowsher M; Hiebert S; Li R; Wang AX; Friborg J; Yu F; Hernandez D; Wang YK; Klei H; Rajamani R; Mosure K; Knipe JO; Meanwell NA; McPhee F; Scola PM
    Bioorg Med Chem Lett; 2018 Jan; 28(1):43-48. PubMed ID: 29162454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
    Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
    PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.
    Smith MA; Lim A
    Drug Des Devel Ther; 2015; 9():6083-94. PubMed ID: 26622169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
    Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
    Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.
    Ali A; Aydin C; Gildemeister R; Romano KP; Cao H; Ozen A; Soumana D; Newton A; Petropoulos CJ; Huang W; Schiffer CA
    ACS Chem Biol; 2013 Jul; 8(7):1469-78. PubMed ID: 23594083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.
    Shen J; Serby M; Reed A; Lee AJ; Zhang X; Marsh K; Khatri A; Menon R; Kavetskaia O; Fischer V
    Drug Metab Dispos; 2016 Aug; 44(8):1164-73. PubMed ID: 27179127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.